Converging Digital ID, AI and Self‑Amplifying mRNA: Toward an AI–Human Genomic Interface

05/01/2026
|In Psychology, 5G Exposed, AI
|By Smombie Gate
Converging Digital ID, AI and Self‑Amplifying mRNA: Toward an AI–Human Genomic Interface
  1. Home
  2. Psychology
  3. Converging Digital ID, AI and Self‑Amplifying mRNA: Toward an AI–Human Genomic Interface

Digital ID and unified health data building an identity linked data stream

Recent developments in the UK illustrate how a national digital identity system combined with centralised health records can create a persistent identity linked data stream about each citizen. After decades of debate Britain is now moving toward a universal digital ID that links all personal records under one profile. The Tony Blair Institute (TBI) heavily funded by Oracle’s Larry Ellison has championed a single digital identity “as the front door” to all public services. Instead of siloed IDs for healthcare taxes etc. one verified ID (likely a smartphone app or biometric login) would access unified databases across government. In TBI’s vision this integration means a person could seamlessly pull up their medical history education social benefits and more in one place. Such an identity linked data pipeline promises personalised always on services: for example combining NHS and employment records to tailor health advice or job recommendations. Indeed TBI touts “personalised always on data driven” interventions as a key benefit of joining up data silos [1].

This centralisation is already underway. In 2022 Blair praised a “shared vision to advance global health” by storing NHS health records in one place for analysis. The UK’s National Health Service holds cradle to grave medical data (dating back to 1948) seen as immensely valuable for AI driven healthcare. With a digital ID linking each person to their NHS file every doctor’s visit prescription lab result or vaccination can be tied to a unique ID profile over a lifetime. This creates a longitudinal health data stream per individual a rich resource for long term AI modelling of health trajectories and outcomes. It also enables precise biological targeting in the sense that authorities or algorithms could identify and reach specific individuals for health interventions based on their data. For example if records show someone has not received a recommended vaccine or screening the system could flag and notify them (or their doctor) immediately. Conversely if data reveal a person’s genomic or medical profile puts them at higher risk for a certain treatment AI could single them out for an adjusted approach. Such targeting is only possible when identity is persistently linked to health data exactly what digital ID + unified records accomplish.

Privacy trade offs. A unified identity data system concentrates sensitive information raising serious privacy and civil liberty concerns. All interactions from hospital visits to job applications to border crossings would funnel through the digital ID creating an unprecedented aggregation of personal data. Privacy advocates warn this could enable “pervasive tracking” and “joined up” surveillance of citizens’ activities. Indeed critics note the push for a single ID dovetails with Oracle’s interest in large analysable datasets: it would generate exactly the unified data pipeline a company like Oracle could host and mine. Tech writer Andrew Orlowski observed that a national digital ID “creates lucrative new opportunities for Oracle a database company” suggesting Tony Blair has become “a salesman for the tech companies” offering magical data solutions to government. In short centralised digital ID plus health data lays the groundwork for continuous monitoring of each person’s biology and behaviour an infrastructure that can feed directly into AI systems [1].

Notably these policy shifts did not happen in a vacuum. Through 2023 to 25 Oracle and Ellison’s teams enjoyed extraordinary access to UK decision makers with 29 meetings with ministers and senior officials in a single year. This lobbying coincided with the government’s U turn to embrace digital ID by late 2025 a plan uncannily similar to TBI’s proposals. In essence tech aligned actors helped catalyse a national identity system that once in place will generate the integrated data streams necessary for advanced AI analytics and targeted bio interventions. As one report quipped the question is “who’s really calling the shots?” the elected officials or the tech giants supplying the infrastructure [1].

Oracle’s AI infrastructure unifying and reasoning over personal health data

Oracle’s Larry Ellison has been explicit that AI’s full potential hinges on unified high dimensional datasets including sensitive health and genomic information. “We need to unify all the national data put it into a database where it’s easily consumable by the AI model and then ask whatever question you like” Ellison told Tony Blair in 2024. In his view governments should aggregate “whatever they’ve got” from spatial and economic stats to electronic health records (EHRs) with genomic data into one massive system for AI to analyse. Only by telling the AI “as much about my country as I can” even citizens’ DNA can it deliver truly transformative insights [4].

Oracle has been positioning itself as the platform to enable this vision. Following its £28B acquisition of Cerner in 2022 (a major EHR provider) Oracle announced plans to build a unified national health records database that pulls data from thousands of hospital systems. The idea is to resolve fragmentation: “Your electronic health data is scattered across dozens of databases… causing tremendous problems” Ellison said pitching a solution where all Americans’ health records (anonymised) reside in one national database. Such a comprehensive repository would give doctors instant access to patient histories and feed anonymised data into AI models to improve diagnosis of diseases like cancer. “Better information is the key to transforming healthcare” Ellison noted enabling better patient outcomes and informed public health policy. This bold plan shows Oracle’s intent to host and synthesise population scale health data for AI [5].

On the technical side Oracle has invested heavily in cloud and AI infrastructure to handle these high dimensional personal datasets. Its Gen2 Cloud uses superclustered NVIDIA GPUs and ultra fast networking to train large models efficiently. This enables Oracle (and partners like hospitals or government agencies) to develop AI systems that can reason over complex medical data. For example at Oracle’s 2025 CloudWorld conference Ellison unveiled tools for hospitals to apply generative AI on patient scans and records to aid diagnostics predicting “better outcomes for millions of patients”. Oracle is also introducing integrated databases that can store and query genomic sequences medical images and sensor data side by side with traditional records. This means an AI could seamlessly cross reference your genome lab results doctor’s notes and even fitness tracker data in its analysis. By breaking data silos Oracle aims to become the one stop system for holistic personal data analytics from genome to daily behaviour all with AI in the loop [6].

The envisioned payoff is deep personalisation of medicine and services. If AI can “think across comprehensive datasets” Ellison predicts it can deliver treatments tailored to each person’s unique profile. For instance AI might analyse a patient’s genes lifestyle and medical history to recommend the optimal therapy for cancer or to predict and prevent a health crisis before it happens. Beyond healthcare unified data could help optimise farming (as Ellison notes analysing crop and soil data to advise farmers) and catch welfare fraud or security threats. In short Oracle pitches itself as providing the “brain” and storage for a new era of governance by data one where big data and AI inform decisions across society [4].

Ubiquitous surveillance. Ellison acknowledges the dystopian side of this vision and even embraces it. He has candidly argued that constant real time monitoring of citizens analysed by Oracle’s machine learning would be socially beneficial by keeping people “on their best behaviour”. In September 2024 Ellison stated that ubiquitous surveillance is “desirable” and something Oracle would “help facilitate” essentially promoting AI oversight as a tool for social order. The logic blurs public health and security: if AI has all data on everyone it can ostensibly catch bad actors prevent crimes or enforce healthy behaviours “surveillance for good” in Ellison’s framing. But this comes at the obvious cost of privacy. It means entrusting our most private information to AI in exchange for its “transformational” benefits. Oracle’s long term strategy thus intertwines massive data aggregation AI driven insight and a willingness to integrate surveillance into societal infrastructure. The company that manages these unified databases (and the AI models on top of them) would wield tremendous power effectively becoming a data gatekeeper for society [4].

In practice Oracle’s influence is already being felt. The company has won over £1 billion in UK government cloud contracts since 2022 including for NHS systems at the same time Ellison’s foundation pledged £257M to Blair’s institute to promote tech forward policies. This symbiosis suggests Oracle is strategically embedding itself in national infrastructures that produce exactly the data its AI platforms need. As Ellison put it bluntly “as long as [countries] put their data all of it in a single place we can use AI to help manage the care of all of the patients and the population at large”. Unifying the data is step one; applying Oracle’s AI is step two. The UK’s unique NHS dataset makes it a prime candidate: “the first thing a country needs to do is unify all of their data so it can be consumed by the AI model” Ellison advised calling the NHS an incredible but fragmented resource. Now with digital IDs and Oracle’s cloud that resource can be consolidated and exploited. The early result may be impressive gains in efficiency and personalised care; the long term result could be an unprecedented concentration of informational power in the hands of Oracle (and its government clients). As observers note “what’s good for Larry Ellison may not be best for the NHS” underscoring the tension between private tech agendas and public interest as we build this AI driven health infrastructure [1][2][4].

Self amplifying mRNA vaccines a replicating platform for personalised therapies

Parallel to data and AI advances a revolutionary biotechnology has emerged: self amplifying mRNA (samRNA) vaccines. These next gen vaccines (also called replicon RNA) build on the mRNA technology deployed during COVID 19 but with a key twist they are designed to replicate inside the body’s cells. In a samRNA vaccine the injected RNA not only encodes a target antigen (e.g. a viral spike protein) but also a replication enzyme (often derived from an alphavirus). Once inside your cells this replicase drives the RNA to copy itself turning the cells into a temporary antigen factory. In effect a samRNA shot behaves like a “synthetic virus” hijacking your cellular machinery to make multiple rounds of the antigen without further doses. A tiny initial dose can thus amplify into a much larger output of protein.

MORE INFO HERE  Lawsuit Filed Against School District For Cell Tower

Proponents argue this amplification could produce stronger or longer lasting immunity with fewer injections. Early trials of samRNA COVID vaccines indeed showed high antibody titres from relatively low microgram doses. This promise has attracted significant backing from global health and defence agencies. The Coalition for Epidemic Preparedness Innovations (CEPI) DARPA and others have heavily funded samRNA platform development seeing it as a rapidly adaptable tool for future pandemics. For example CEPI in 2023 announced support for a thermostable self amplifying mRNA vaccine platform to enable 100 day responses to Disease X [7]. DARPA’s earlier programmes similarly aimed to harness nucleic acid vaccines that could be designed and deployed in weeks not years [8]. The attractiveness is clear: samRNA is a software like medical countermeasure once you have the RNA code you can quickly manufacture immunity on demand.

However the scientific behaviour of samRNA in the body raises new challenges. Unlike conventional vaccines that deliver a fixed dose of antigen and then wane a replicating mRNA could persist and keep producing antigen for an unknown duration. The “dose” a person ultimately receives is not just what’s in the syringe but how much RNA their cells end up copying which can vary by individual biology. This makes it harder to predict or control the exposure. Indeed a Phase I trial of a samRNA COVID vaccine in Uganda found that by the second dose 93% of participants experienced severe Grade ≥3 laboratory abnormalities (such as dangerously low blood cell counts). These adverse effects thrombocytopenia lymphopenia neutropenia intensified after the second injection suggesting a cumulative toxicity as the replicating RNA kept the immune system under stress. Over 85% of subjects also had systemic reactions (fever vomiting etc.) indicating a strong inflammatory response. Notably this trial involved healthy adults; the effects on vulnerable or immunocompromised people are still unknown [3].

Scientists have likened replicating mRNA to unleashing a “self replicating synthetic virus” inside the patient. The analogy is apt: you are essentially infecting the person with a benign virus that forces their cells to churn out the pathogen’s protein. This blurs the line between vaccination and gene therapy (or infection). Safety oversight becomes a major concern traditional pharmacovigilance assumes a drug or vaccine dissipates after a short time but a replicon may linger making it harder to know when side effects might emerge or subside. There is also the specter (albeit theoretical) of genomic interaction. SamRNA doesn’t integrate into DNA but the presence of a replicase inside human cells opens possibilities: might it accidentally copy other RNA strands? Could prolonged antigen production trigger autoimmune issues or unforeseen gene expression changes in cells? Researchers have warned that “undefined synthetic mRNA replication” carries risks of uncontrolled antigen production and unpredictable cellular effects. Regulators are grappling with these unknowns. Nonetheless in late 2025 and early 2026 authorities in the EU Japan India and the UK’s MHRA moved forward with approvals of samRNA COVID vaccines (such as Arcturus’s Kostaive (ARCT 154)) prioritising potential public health benefits over the red flags from trials. Critics blasted the UK approval as a “catastrophic mistake” accusing a captured “Bio Pharmaceutical Complex” of pushing experimental genetic technology onto the public [3].

From an AI and personalised medicine standpoint self amplifying mRNA represents a new kind of therapeutic platform one that is essentially programmable. Because the payload is just information (an RNA sequence coding for a protein) it is conceivable that AI systems could design or tailor these vaccines on the fly. In a data rich healthcare system an AI might detect an emerging pathogen or cancer marker and rapidly generate an appropriate samRNA sequence to address it. Unlike traditional drugs which take years to formulate and mass produce RNA sequences can be algorithmically designed and synthesised in days. For example researchers have already used AI to design proteins and guide RNA constructs for gene modulation tasks. Extending this to vaccines: an AI model given the genomic sequence of a new virus could propose an optimal immunogenic RNA design within minutes. Ellison’s vision of unified data and AI enabled health care aligns with this he notes that with all data in one place you could ask the AI any question including how to treat an emerging illness. Oracle’s cloud could then rapidly deploy that solution via a platform like samRNA [2][4].

Crucially samRNA also opens the door for personalised vaccines or therapeutics. Since the RNA can be tailored one can imagine customising the vaccine for different sub populations or even individuals. An AI might recommend slight sequence modifications or dosage tweaks based on a person’s genetic profile medical history or real time health indicators. If unified health data reveals that certain genetic variants correlate with adverse reactions to a replicon vaccine the AI could flag those individuals before injection. It might suggest an alternative therapy for them or a lower dose whereas others get a standard dose. In the optimistic scenario AI guided samRNA therapies could achieve a highly precise fit the right antigen delivered at the right strength in the right patient at the right time. This is essentially personalised immunotherapy at scale. During a pandemic for instance an AI could segment the population by risk factors and generate different RNA vaccine formulations for each segment (one size need not fit all). Oracle’s Larry Ellison has highlighted this kind of personalisation as a key benefit of having rich data: treatments can be tailored to one’s unique medical and genetic makeup. With samRNA that tailoring can occur at the molecular design level not just in downstream care [2][4].

Yet these advancements mandate intensive bio surveillance. If 90% of people getting a samRNA shot experience at least mild adverse effects health systems must closely track symptoms follow ups and potentially long term outcomes. Digital health IDs and unified records would be indispensable for monitoring vaccine recipients in real time. Authorities could link each person’s vaccination status (recorded via digital ID) to subsequent health data enabling AI to detect patterns e.g. flagging if certain demographics show rare side effects or if booster timing should change. In essence the vaccine becomes a data generating device inside the body and the digital infrastructure captures its effects. This creates a continuous feedback loop: data → AI analysis → adjusted intervention. As we’ll explore next that loop is central to how AI can function as a “decision engine” for personalised adaptive biological interventions [3].

AI decision engines personalising interventions via continuous feedback loops

A defining feature of an AI driven health system is the closed feedback loop between data collection algorithmic decision making and real time intervention. With digital ID linked data streams and new bio digital tools (like samRNA vaccines or wearable sensors) we are moving toward a model of healthcare (and governance) that is proactive personalised and adaptive by default. In this model AI acts as the decision engine: it continuously processes incoming data about individuals determines if an intervention is needed tailors a response and then monitors the outcome looping back into new data.

We already see early glimmers of such loops. For instance in diabetes care closed loop insulin delivery systems use continuous glucose monitors and AI based algorithms to adjust a patient’s insulin pump in real time without manual input. These so called “artificial pancreas” systems continuously sense blood sugar and algorithmically dispense the right insulin dose every few minutes preventing dangerous highs or lows. It’s a prime example of an algorithm dynamically personalising a biological intervention (hormone delivery) based on sensor data feedback. Over days and weeks the system learns and adapts to the individual’s patterns. This concept sense analyse act and learn can be expanded to many aspects of health.

Imagine applying it at population scale with AI oversight. Sensors and data feeds. Citizens carry smartphones wearables or even implantable devices that measure various parameters (heart rate blood pressure activity perhaps one day biochemical markers). Their digital ID ensures all these data points link back to their unified profile. Simultaneously external data like environmental conditions disease outbreaks or public safety information stream into the system. Analysis. National AI platforms (run on Oracle’s cloud or similar) continuously ingest these multidimensional data. The AI trained on vast historical and genomic data detects patterns and outliers. It might predict that a certain neighbourhood is at risk of a COVID outbreak next week (based on subtle upticks in symptom reports and mobility data) or that a specific individual is trending toward a health crisis (based on vitals and medical history). Decision. Once an issue is flagged the AI can trigger an intervention. For a community outbreak risk it might formulate a targeted vaccination or alert campaign. For the individual on a dangerous health trajectory it might recommend a personalised medication adjustment schedule an urgent check up or even dispatch a drone with a medical kit whatever the algorithm deems optimal. Implementation. Thanks to digital integration many interventions can be delivered automatically or with minimal human input. If it’s information or advice a notification pops up in the person’s health app. If it’s a physical measure like a drug the system could route a prescription to their pharmacy or adjust their smart injector device. The key is that the decision to action loop is highly automated and data driven.

Continuous learning. After the intervention the system monitors new data to see the effect. Did the neighbourhood’s case numbers drop? Did the individual’s vitals improve? This outcome feeds back to the AI which updates its models (learning which interventions work and which don’t). Such iterative optimisation means the longer the system runs the smarter and more fine tuned it becomes for each person and context. Over time the AI might learn for example that a certain genomic profile responds better to one blood pressure drug than another and will thereafter personalise prescriptions accordingly.

The NHS unified data + Oracle AI infrastructure is being tailored for exactly this kind of loop. Ellison notes that if you centralise all patient data “we can use AI to help manage the care of all of the patients and the population at large”. That implies a system where AI not only assists human decisions but potentially automates many decisions across millions of people simultaneously [4]. Tony Blair’s institute explicitly talks about using integrated data to deliver “personalised always on” services and proactive interventions from government. For example TBI suggests that by linking databases authorities could identify needs and act before citizens even request help such as auto enrolling someone in a benefit or sending tailored health advice based on their profile. Translated to health and genomics this could mean the system identifies that you have a high genetic risk for a disease and preemptively offers you screening or gene therapy without you having to ask [1].

MORE INFO HERE  New Study: Wireless Radiation Negatively Impacts Human Cells  

During the COVID 19 pandemic we saw a crude version of AI assisted decision loops with contact tracing apps and exposure notifications. But future systems will be far more granular. Consider vaccine compliance. In a fully digital ID regime proof of vaccination can be seamlessly checked for any public activity (as was trialled with QR code passes). An AI could continuously monitor the national immunisation database and flag individuals who haven’t received the latest recommended booster. The system might then automatically send those people reminders or even apply escalating nudges: first a friendly notification later perhaps restricting their access to certain venues until they comply. This is a feedback loop enforcing policy via data. In China’s COVID response we glimpsed this with health code apps turning red to bar entry for the unvaccinated a tightly coupled data driven control system. Western implementations might start softer but the architecture makes such algorithmic enforcement feasible.

Another example is personalised dosing of therapies. If a future AI finds that 10% of vaccine recipients (identified by a genetic marker in their health record) are experiencing strong side effects it could recommend those individuals receive a half dose or an alternative formula. Their digital ID profile would be tagged so when they arrive at a clinic the nurse’s AI guided interface says “give this person variant B of the vaccine.” In essence AI becomes the brain coordinating myriad micro decisions in healthcare delivery that used to be one size fits all or left to human discretion. The system continuously updates these decisions as new data flow in a real time adaptive management of human biology and behaviour.

The convergence of technologies makes this possible. Oracle’s cloud can ingest enormous data in real time (e.g. IoT streams from wearables). National digital ID ensures every data point and action is tied to the right person. AI algorithms serve as the “central nervous system” analysing signals and issuing commands. And new biotechnologies (samRNA vaccines gene therapies smart devices) serve as the “actuators” that carry out the AI’s decisions within our bodies or environments. This effectively creates an AI mediated interface with human biology. Just as thermostats automatically regulate a house’s climate we will have AI regulators adjusting our internal “settings” to maintain or improve health [2][6].

There are profound ethical and autonomy questions here. A system built to optimise outcomes might overstep personal choice the line between personalised care and paternalistic control can blur. If an algorithm determines you should take a certain genetic therapy to reduce future disease risk will you have the right to refuse? And if you refuse could there be automated consequences (higher insurance premiums restricted access to public spaces)? The technology enables a form of “predictive and preventive governance” that catches issues before they manifest but it also risks eroding individual freedom in the name of collective good. People may be nudged or even coerced by automated systems that “know best” based on your data. As one analysis put it this could lead to a technocratic paternalism or even soft authoritarianism “where personal autonomy yields to what the data says is best.”

Biosecurity initiatives and data infrastructure connecting DARPA CEPI and Oracle

The convergence of digital data and biotechnologies isn’t happening by accident it’s driven in part by national security and pandemic preparedness agendas. Agencies like DARPA (the U.S. Defense Advanced Research Projects Agency) and global coalitions like CEPI have been investing in programmable RNA platforms pathogen surveillance and rapid response capabilities which dovetail with the data infrastructure companies like Oracle are building.

DARPA recognised early that the old model of vaccine development was too slow for modern threats. In 2017 it launched the Pandemic Prevention Platform (P3) to create an integrated end to end system that could halt a novel viral outbreak within 60 days of detection. Achieving that meant leveraging nucleic acid technologies (DNA/RNA vaccines and even genetic antibody recipes) and automating the pipeline from pathogen gene sequencing → therapeutic design → production at scale [8]. One DARPA programme manager explained their goal: “a technology platform that can place a protective treatment in providers’ hands within 60 days of a pathogen being identified”. Implicit in that vision is a robust surveillance and data component: you must detect the pathogen immediately share its genomic sequence and have AI/algorithms ready to design a countermeasure. This anticipates a tight integration between bioinformatics data streams (from labs hospitals environmental sensors) and the therapeutic response system. Oracle’s pursuit of unified health data can be seen as complementary or even foundational to this. A unified database of clinical and genetic data could enable early anomaly detection (e.g. an uptick in unusual respiratory cases flagged by AI) and speed up identifying the pathogen’s genome if samples are in the system. In other words bio surveillance requires big data. It’s telling that DARPA also invested in rapid diagnostics and even AI for outbreak prediction; those capabilities would rely on aggregating data from many sources (something Oracle’s national data cloud could facilitate) [4].

CEPI launched in 2017 after the Ebola outbreak has a similar mandate to compress vaccine development timelines to “100 days” for any new epidemic threat. CEPI has heavily funded novel RNA vaccine platforms including self amplifying mRNA exactly because they are plug and play once you have a pathogen’s genetic code. For instance CEPI announced in 2023 a partnership to optimise a saRNA vaccine platform that could be quickly adapted to “Disease X” [7]. This platform approach envisions a library of RNA templates and the manufacturing capacity to produce vaccines almost on demand. But to use it effectively one needs a pipeline to know what strain or antigen to encode where an outbreak is happening and who should get the vaccine first. That comes back to data and AI. A globally integrated surveillance system (genomic sequencing labs electronic health records even search engine trends) would feed an AI that identifies an emerging pathogen. Then the RNA vaccine platform swings into action potentially guided by AI optimisations (choosing the best antigen target etc.). Finally digital infrastructure ensures the right people are vaccinated in time.

This is where Oracle’s role becomes salient. Oracle has experience building large scale data systems for government health responses. During COVID 19 Oracle collaborated with the U.S. government to create a web platform that collected real time data on off label drug use and patient outcomes. At one point Ellison himself advocated for a system to crowdsource treatment results (e.g. of hydroxychloroquine) and “collect data in real time” from doctors and patients to quickly see what works. This Therapeutic Learning System which Oracle donated aimed to accelerate decision making by gathering nationwide clinical data into one database. While controversial it demonstrated Oracle’s approach: use cloud databases to enable rapid data driven feedback during a health crisis [9]. One can easily imagine similar Oracle powered dashboards in a future pandemic where data from hospitals around the country (or world) flows into a central AI that guides public health actions in near real time.

Moreover Oracle’s cloud and data expertise could be directly useful for DARPA or CEPI projects. For example Ellison’s vision of an anonymised national EHR database for the US includes using that data to build AI models for disease detection and diagnosis. A side benefit is that anomalies (like unusual clusters of symptoms) could surface faster when all data is pooled. If a new pathogen arises an AI trawling a unified health database might catch subtle signals (ER visits lab test abnormalities) sooner than individual doctors would effectively serving as an early warning system. Additionally the genomic data Oracle wants to include could feed into tracking pathogen evolution (since patient samples and sequences might be stored). Indeed public health agencies increasingly rely on big data analytics something Oracle’s platforms are designed to provide at scale [4][5].

The involvement of defence and biosecurity stakeholders also ensures significant funding and urgency behind these converging technologies. When the UK approved the Kostaive samRNA vaccine in 2026 it was not only a public health decision but part of a broader biosecurity strategy to have cutting edge countermeasures. The UK’s Visionary Innovation (with Blair and Ellison’s influence) sees being ahead in AI and genomics as a national competitive edge. Governments militaries and NGOs are all investing in the notion of “data driven biosecurity.” The logic is compelling: if you can monitor global health data in real time (like a weather map for disease) you can contain threats faster. If you have AI that can rapidly design a vaccine or therapy you can neutralise those threats before they explode. And if you have a digital ID infrastructure you can deploy interventions to the exact people who need them and verify compliance [3].

Oracle’s recent partnerships hint at this alignment. The UK’s NHS deal with Oracle to centralise data and the parallel push for digital IDs mean the UK could become a model testbed for such an integrated bio surveillance network. It’s no coincidence that Blair and Ellison’s efforts converged in 2025: digital ID policy gained momentum just as Oracle scaled up its AI cloud and as samRNA vaccines emerged from R&D to real world use. Each piece enhances the others. A digital ID system provides clean continuous data for AI. Advanced AI provides analysis and decision support for biomedical programmes. And programmable biotech provides the actionable output (vaccines therapies) to close the loop. Institutions like DARPA and CEPI see the potential and are likely coordinating with tech providers to ensure the infrastructure can support their missions. In essence the traditionally separate domains of cybersecurity public health and national defence are fusing into a single paradigm: keep the population safe (from viruses bioweapons etc.) by monitoring and managing biological information at scale. Oracle’s databases and AI are poised to be the backbone for that paradigm enabling agencies to run complex models and simulations on population data or to track the deployment of medical countermeasures in real time [1][4].

MORE INFO HERE  Wireless Radiation: Thousands Demonstrate at International Agency for Research on Cancer Headquarters in France

From personalised vaccines to AI mediated gene regulation the next frontier

Looking further ahead the convergence of AI big data and biotechnology suggests a trajectory toward AI systems interfacing with the human genome and epigenome in more direct ways. Self amplifying mRNA vaccines are an early step essentially AI designed code (mRNA) altering cellular behaviour temporarily. But future interventions could go beyond vaccines to fine tuned control of gene expression or cell programming in individuals all guided by AI and data.

Modern biology has revealed that we don’t necessarily need to edit DNA to influence health; we can often achieve desired outcomes by turning existing genes on or off at the right time (epigenetics) or by inserting transient genetic instructions (like mRNA or gene therapy vectors) that eventually fade. This is fertile ground for AI because the gene networks and epigenetic patterns involved are enormously complex ideal for machine learning to decipher. As our ability to read a person’s genome (and epigenome) improves AI could identify which genes or pathways should be modulated to treat or prevent a condition. The question then becomes: how to modulate them?

Enter emerging tools like CRISPR based gene regulation (CRISPRi/a) and epigenetic editing. These techniques allow scientists to upregulate or downregulate specific genes without permanently altering the DNA sequence. For example CRISPR interference uses a “dead” Cas9 protein to deliver repressors or activators to a target gene’s promoter effectively switching that gene off or on at will. Recently researchers demonstrated combining AI designed proteins with CRISPR to achieve highly selective gene activation. A team at University of Washington created an AI designed protein that binds to an epigenetic silencer (the PRC2 complex) and paired it with CRISPR/dCas9 to target specific genes the result was the ability to “safely upregulate specific genes… without permanently changing the genome” [10]. In their 2022 report they toggled on genes that had been silenced effectively overriding the cell’s off switches in a controlled way. This proof of concept highlights that AI can help design molecules to precisely modulate gene expression (in this case by targeting epigenetic markers that sit above the genome to silence or activate genes). The beauty as the authors noted is that this approach can alter cell function “without permanently changing the genome and causing unintended mistakes.”

Now project forward: an AI with access to your complete genomic and epigenetic data might suggest for instance that boosting expression of a certain gene in your liver for a while could stave off a metabolic disease you’re at risk for. Instead of editing your genes your doctor (or AI agent) could administer a therapy that uses a CRISPR epigenetic modulator to turn that gene on at a moderate level for a defined period. Perhaps this is delivered via a lipid nanoparticle containing mRNA that encodes the dCas9 and AI designed activator protein (another fusion of samRNA like delivery with precision gene control). The intervention could later be removed or wear off and your underlying DNA remains unchanged. This is a scenario where AI interacts with your genomic circuitry in real time making tweaks analogous to software patches in a computer system except the “software” is your gene expression profile [10].

Epigenetic states (like DNA methylation patterns or histone modifications) are also critical in diseases from cancer to ageing. AI is already being used to parse patterns in epigenomic data. In the future if your epigenetic markers indicate high stress on certain pathways (say due to environmental exposures) an AI might recommend targeted lifestyle changes and perhaps an epigenetic therapy to counteract those changes. For example some experimental therapies aim to rejuvenate cells by resetting epigenetic marks (a concept in some anti ageing research) [11]. An AI could decide when a person’s cells need a “reboot” and trigger a treatment that transiently expresses Yamanaka factors (genes that can reverse epigenetic age) in a safe controlled manner. This sounds like science fiction but early animal studies are exploring it and AI would be essential to avoid cancerous outcomes by finding the right balance.

Another realm is personalised gene therapies. With advances in safe viral vectors and lipid nanoparticles it’s conceivable that in a decade or two if you have a genetic deficiency an AI might design a bespoke genetic fix for you. For instance if you have a unique mutation the AI could tailor a base editing fix specific to your sequence. Already AI helps optimise guide RNAs and predict off target effects for CRISPR. This personalisation could extend to somatic gene editing done as needed throughout life. Importantly the AI’s decisions here would rely on continuous data it might monitor your blood for biomarkers and only trigger a gene intervention when those markers exceed a threshold (closing the loop of sense decide act again) [12].

From vaccines to “digital gene therapy”. We can think of self amplifying mRNA vaccines as an initial platform where AI picks a genetic message (antigen) to send into your body for a beneficial outcome (immunity). Future platforms might send more complex messages e.g. small gene circuits or instructions to boost a protein that your body needs. Since these messages don’t necessarily alter your genome permanently they could be deployed periodically almost like software updates or personalised medicine “apps.” This would truly be an AI human genomic interface: AI systems continuously analyse your biological data and deploy genetic or epigenetic interventions to optimise health and prevent disease. Your body becomes in a sense an adaptive biological system under semi automated management.

Of course this raises profound questions of consent equity and oversight. Who controls the AI? Who decides the goals (e.g. what counts as an “improvement” to target)? There are also scientific uncertainties intervening in gene expression can have ripple effects. But the trajectory is apparent. We started with blunt tools (one size fits all pills vaccines surgeries) applied reactively. We’re moving into an era of precision data driven predictive interventions applied proactively. If today’s cutting edge is a tailored cancer immunotherapy based on your tumour genomics tomorrow’s could be an AI guided daily regimen that modulates your immune cells or gene activity to never let the tumour arise in the first place.

In summary the path from personalised vaccines to AI guided gene regulation is a continuum of increasing integration between digital intelligence and human biology. Each advancement be it digital IDs logging our health AI modelling our risks samRNA delivering custom code to our cells or CRISPR tools allowing on demand gene switches is a step toward a future where AI collaborates with our genomes to maintain and enhance our health. It’s a future where disease might be headed off long before symptoms where ageing could be managed by periodic genomic tune ups and where one’s biological state is in constant dialogue with an artificial intelligence. Ensuring that dialogue respects human autonomy and values will be as important as the technologies themselves.

Joining the dots on convergence AGI and transhumanism

The developments traced in this analysis unified health data streams enabled by digital IDs AI platforms like Oracle’s aggregating and reasoning over genomic information and programmable biotechnologies such as self amplifying mRNA serving as actuators for precise interventions are often discussed in isolation. Public discourse treats digital identity as a convenience issue centralised health records as an efficiency measure and advanced vaccines or gene therapies as mere medical progress. Yet as this report illustrates they converge to create a powerful infrastructure: an AI mediated interface with human biology capable of monitoring predicting and modifying our internal states in real time.

This convergence feeds directly into the broader race for artificial general intelligence (AGI) where a handful of private individuals and companies pour trillions into automating human cognition itself. As AI researcher Tristan Harris and others in industry circles have described in private and public discussions the goal is not better chatbots but an intelligence that outperforms humans in every cognitive domain accelerating discoveries in medicine strategy and beyond by automating the very process of problem solving [13]. Leading figures view AGI as a path to unparalleled power economic dominance military superiority and even transhumanist ideals: reversing ageing curing all disease and transcending biological limits through perfect mastery of biology’s “language”.

Private conversations among those at the helm reveal a deterministic mindset laced with transhumanist undertones a quasi religious thrill in birthing a superior digital entity and a willingness to accept substantial risks of catastrophe for the chance at utopia or immortality. Some rationalise rolling the dice on humanity’s future believing the race inevitable and the worst outcomes mitigated by ego driven transcendence: birthing a “digital god” that outlives biological life. This is not democratic governance but a small cadre of tech leaders deciding humanity’s trajectory often in silos that mask the interconnected stakes.

By joining these dots we see the full picture: the bio digital systems emerging today provide the data interfaces and feedback loops essential for AGI to extend its reach into human genomes and bodies. What begins as personalised medicine risks evolving into transhumanist reconfiguration under competitive pressures that prioritise dominance over safety or consent. The path is not predetermined but it demands urgent recognition: private incentives are shaping a future where AI could manage not just health but human potential itself. Society must connect these threads assert collective oversight and redirect toward outcomes that preserve autonomy and shared values before a few individuals’ vision becomes irreversible reality.

Sources

© 2026 Smombie Gate | 5G | EMF. All rights reserved